The global spinal biologics industry is projected to reach $2.3 billion by 2027, growing at a compound annual growth rate of 2.8 percent, according to ReportLinker.com.
Biologics
Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics.
Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA.
Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release.
A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.
Advertisement
Voters approved a proposition to provide $5.5 billion for stem cell research by the California Institute of Regenerative Medicine, according to a Nov. 13 press release.
The first human clinical trial using stem cells to treat spina bifida has been made possible thanks to a $9 million grant provided Nov. 12 by the California Institute for Regenerative Medicine.
CelluBridge, a spinal cord scaffold implant, has received the FDA's breakthrough device designation.
A man who had shoulder pain turned to stem cells to aid his recovery from rotator cuff surgery, according to a Nov. 11 report from ABC12.
Cerapedics' i-Factor+ Matrix is now available for surgical implantation in Canada.